Genethon will benefit from his international experience with responsibility for the development of new drugs within major pharmaceutical companies such as Pfizer and Rhone-Poulenc Rorer. Also, he contributed to the creation of the Drug for Neglected Diseases Initiative (DNDi) - of which he was president from 2003 to 2007. The DNDi is a foundation dedicated to the research and development of new drugs against neglected parasite diseases affecting poor populations. Finally, with Pierre Tambourin, he has been deeply involved in the development of Genopole(R) Evry, and is president of the board of directors of the pre-seed fund G1J Ile-de-France.